Experimental studies have demonstrated that knockdown of EN1 triggers potent and selective apoptosis in cancer cells, while overexpression of EN1 in normal cells leads to the activation of survival pathways, thereby conferring resistance to standard chemotherapeutic agents. Here, EN1 is linked to cancer.